117 related articles for article (PubMed ID: 9052472)
21. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
22. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.
Kuhn EJ; Kurnot RA; Sesterhenn IA; Chang EH; Moul JW
J Urol; 1993 Nov; 150(5 Pt 1):1427-33. PubMed ID: 8105108
[TBL] [Abstract][Full Text] [Related]
23. Heregulin degradation in the absence of rapid receptor-mediated internalization.
Baulida J; Carpenter G
Exp Cell Res; 1997 Apr; 232(1):167-72. PubMed ID: 9141633
[TBL] [Abstract][Full Text] [Related]
24. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
[TBL] [Abstract][Full Text] [Related]
25. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
26. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
27. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
28. Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells.
Li W; Park JW; Nuijens A; Sliwkowski MX; Keller GA
Oncogene; 1996 Jun; 12(11):2473-7. PubMed ID: 8649790
[TBL] [Abstract][Full Text] [Related]
29. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
30. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
31. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues.
Cohen DW; Simak R; Fair WR; Melamed J; Scher HI; Cordon-Cardo C
J Urol; 1994 Dec; 152(6 Pt 1):2120-4. PubMed ID: 7525998
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer.
Morote J; de Torres I; Caceres C; Vallejo C; Schwartz S; Reventos J
Int J Cancer; 1999 Aug; 84(4):421-5. PubMed ID: 10404097
[TBL] [Abstract][Full Text] [Related]
33. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
35. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
36. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
Chang H; Riese DJ; Gilbert W; Stern DF; McMahan UJ
Nature; 1997 May; 387(6632):509-12. PubMed ID: 9168114
[TBL] [Abstract][Full Text] [Related]
37. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.
Ross JS; Nazeer T; Church K; Amato C; Figge H; Rifkin MD; Fisher HA
Cancer; 1993 Nov; 72(10):3020-8. PubMed ID: 8106140
[TBL] [Abstract][Full Text] [Related]
38. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling.
Carraway KL; Cantley LC
Cell; 1994 Jul; 78(1):5-8. PubMed ID: 8033211
[No Abstract] [Full Text] [Related]
39. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
[TBL] [Abstract][Full Text] [Related]
40. A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4.
Higashiyama S; Horikawa M; Yamada K; Ichino N; Nakano N; Nakagawa T; Miyagawa J; Matsushita N; Nagatsu T; Taniguchi N; Ishiguro H
J Biochem; 1997 Sep; 122(3):675-80. PubMed ID: 9348101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
